These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38224406)

  • 1. S288T mutation altering MmpL3 periplasmic domain channel and H-bond network: a novel dual drug resistance mechanism.
    Ge Y; Luo Q; Liu L; Shi Q; Zhang Z; Yue X; Tang L; Liang L; Hu J; Ouyang W
    J Mol Model; 2024 Jan; 30(2):39. PubMed ID: 38224406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of SQ109 analogs binding to mycobacterium MmpL3 transporter using MD simulations and alchemical relative binding free energy calculations.
    Stampolaki M; Stylianakis I; Zgurskaya HI; Kolocouris A
    J Comput Aided Mol Des; 2023 Jun; 37(5-6):245-264. PubMed ID: 37129848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.
    Tahlan K; Wilson R; Kastrinsky DB; Arora K; Nair V; Fischer E; Barnes SW; Walker JR; Alland D; Barry CE; Boshoff HI
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1797-809. PubMed ID: 22252828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
    Li W; Upadhyay A; Fontes FL; North EJ; Wang Y; Crans DC; Grzegorzewicz AE; Jones V; Franzblau SG; Lee RE; Crick DC; Jackson M
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6413-23. PubMed ID: 25136022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature.
    Imran M; Arora MK; Chaudhary A; Khan SA; Kamal M; Alshammari MM; Alharbi RM; Althomali NA; Alzimam IM; Alshammari AA; Alharbi BH; Alshengeti A; Alsaleh AA; Alqahtani SA; Rabaan AA
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specifically Targeting Mtb Cell-Wall and TMM Transporter: The Development of MmpL3 Inhibitors.
    Luo Q; Duan H; Yan H; Liu X; Peng L; Hu Y; Liu W; Liang L; Shi H; Zhao G; Hu J
    Curr Protein Pept Sci; 2021 Oct; 22(4):290-303. PubMed ID: 33882806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational design of MmpL3 inhibitors for tuberculosis therapy.
    Chaitra R; Gandhi R; Jayanna N; Satyanath S; Pavadai P; Murahari M
    Mol Divers; 2023 Feb; 27(1):357-369. PubMed ID: 35477825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Modelling and Atomistic Insights into the Binding Mechanism of MmpL3 Mtb.
    Kwofie SK; Hanson G; Sasu H; Enninful KS; Mensah FA; Nortey RT; Yeboah OP; Agoni C; Wilson MD
    Chem Biodivers; 2022 Sep; 19(9):e202200160. PubMed ID: 35969844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450.
    Bukhdruker S; Varaksa T; Grabovec I; Marin E; Shabunya P; Kadukova M; Grudinin S; Kavaleuski A; Gusach A; Gilep A; Borshchevskiy V; Strushkevich N
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition Mechanism of Anti-TB Drug SQ109: Allosteric Inhibition of TMM Translocation of Mycobacterium Tuberculosis MmpL3 Transporter.
    Carbone J; Paradis NJ; Bennet L; Alesiani MC; Hausman KR; Wu C
    J Chem Inf Model; 2023 Aug; 63(16):5356-5374. PubMed ID: 37589273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the oligomeric state of mycobacterial membrane protein large 3 and its interaction with SQ109 with native cell membrane nanoparticles system.
    Qiu W; Guo Y
    Biochim Biophys Acta Biomembr; 2022 Feb; 1864(1):183793. PubMed ID: 34655545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Inhibitors to MmpL3 Transporter of
    Choksi H; Carbone J; Paradis NJ; Bennett L; Bui-Linh C; Wu C
    ACS Omega; 2024 Mar; 9(12):13782-13796. PubMed ID: 38559933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target.
    Zhang B; Li J; Yang X; Wu L; Zhang J; Yang Y; Zhao Y; Zhang L; Yang X; Yang X; Cheng X; Liu Z; Jiang B; Jiang H; Guddat LW; Yang H; Rao Z
    Cell; 2019 Jan; 176(3):636-648.e13. PubMed ID: 30682372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for the Inhibition of Mycobacterial MmpL3 by NITD-349 and SPIRO.
    Yang X; Hu T; Yang X; Xu W; Yang H; Guddat LW; Zhang B; Rao Z
    J Mol Biol; 2020 Jul; 432(16):4426-4434. PubMed ID: 32512002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3.
    Hu T; Yang X; Liu F; Sun S; Xiong Z; Liang J; Yang X; Wang H; Yang X; Guddat LW; Yang H; Rao Z; Zhang B
    Structure; 2022 Oct; 30(10):1395-1402.e4. PubMed ID: 35981536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.
    McNeil MB; O'Malley T; Dennison D; Shelton CD; Sunde B; Parish T
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33055263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.
    Jia L; Coward L; Gorman GS; Noker PE; Tomaszewski JE
    J Pharmacol Exp Ther; 2005 Nov; 315(2):905-11. PubMed ID: 16085758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore based virtual screening & molecular docking approach for identification of mycobacterial membrane protein large 3 (MmpL3) inhibitors.
    Dhulap A; Banerjee P
    J Biomol Struct Dyn; 2023 Dec; 41(20):11062-11077. PubMed ID: 36571432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections.
    North EJ; Schwartz CP; Zgurskaya HI; Jackson M
    Expert Opin Drug Discov; 2023 Jul; 18(7):707-724. PubMed ID: 37226498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis.
    Belardinelli JM; Yazidi A; Yang L; Fabre L; Li W; Jacques B; Angala SK; Rouiller I; Zgurskaya HI; Sygusch J; Jackson M
    ACS Infect Dis; 2016 Oct; 2(10):702-713. PubMed ID: 27737557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.